Retrospective Analysis of Healthcare Resource Use, Treatment Patterns, and Treatment-related Events in Patients with Huntington's Disease-associated Chorea Initiated on Tetrabenazine

Journal of Health Economics and Outcomes Research
Victor W SungKaren E Anderson

Abstract

Huntington's disease (HD) is a multifaceted neurodegenerative disorder characterized by involuntary movements, specifically chorea, as well as behavioral and psychiatric disturbance, and cognitive dysfunction. Tetrabenazine was the first approved treatment for chorea, although tolerability concerns exist. To characterize demographic and clinical characteristics of HD patients with chorea based on tetrabenazine use and examine treatment persistence with tetrabenazine in a real-world setting. Patients with a claim for HD-associated chorea (ICD-9-CM code 333.4) between 1/1/08 and 9/30/15 were selected from the MarketScan® Commercial and Medicare Supplemental databases. The first diagnosis date during the study period was considered the index date, with ≥6 months of continuous medical and prescription coverage before and after the index date. Treatment persistence was defined as the number of days from initiation to discontinuation or end of follow-up period. Discontinuation was defined as a gap in therapy of ≥60 days. 1644 patients met selection criteria (mean age ± standard deviation: 54.5 ± 15.5), of which 151 (9.2%) were treated with tetrabenazine during the study period. The average (median) daily dose of tetrabenazine during ...Continue Reading

References

May 14, 1996·Proceedings of the National Academy of Sciences of the United States of America·J D EricksonE Weihe
Jan 14, 1999·Journal of Neurology, Neurosurgery, and Psychiatry·T ForoudP M Conneally
Aug 5, 2005·The New England Journal of Medicine·Lars Osterberg, Terrence Blaschke
Nov 30, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher KenneyJoseph Jankovic
Aug 15, 2009·Lancet Neurology·Joseph Jankovic
Nov 26, 2009·Expert Opinion on Pharmacotherapy·Alfonso Fasano, Anna Rita Bentivoglio
Aug 11, 2010·Drug News & Perspectives·Liming Shao, Michael C Hewitt
Apr 19, 2011·Handbook of Clinical Neurology·Karen E Anderson
Mar 13, 2014·Nature Reviews. Neurology·Christopher A RossSarah J Tabrizi
Mar 13, 2014·Journal of the American Association of Nurse Practitioners·Mary Ellen RobertsMary B Neiheisel
Aug 30, 2014·Expert Opinion on Drug Safety·Christian LeporiniEmilio Russo
Jul 6, 2016·JAMA : the Journal of the American Medical Association·UNKNOWN Huntington Study GroupEmily Christopher
Jul 28, 2016·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·C JonesR T Edwards
Dec 17, 2016·Journal of Huntington's Disease·Jennifer A SimpsonGeorge J Yohrling
Mar 8, 2017·Journal of Clinical Movement Disorders·Daniel O ClaassenDavid Stamler
Jul 12, 2017·JAMA Neurology·Samuel FrankUNKNOWN Huntington Study Group/Alternatives for Reducing Chorea in Huntington Disease Investigators

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Nature Reviews. Drug Discovery
Michael R HaydenPeter Kirkpatrick
© 2021 Meta ULC. All rights reserved